Abstract:figure legend Circulating noradrenaline (NA) stimulates the release of neuropeptide Y (NPY) from presynaptic sympathetic nerve terminals via activation of β‐adrenergic receptors (β‐R). This NA‐induced NPY release can be inhibited by the β‐blocker propranolol, suggesting that this mechanism, which enhances sympathoexcitation, is mediated via β‐adrenergic receptors. Cardiac disease is marked by sympathoexcitation and elevated levels of noradrenaline (NA) and cotransmitter neuropeptide Y (NPY). Increased NPY levels are associated with a greater risk of ventricular arrhythmias and mortality. Nonetheless, the factors that cause NPY release remain poorly understood. We hypothesized that circulating catecholamines might lead to NPY release from myocardial sympathetic nerve terminals via a β‐receptor‐mediated mechanism that enhances sympathoexcitation. Ventricular interstitial NA and NPY levels were measured in six Yorkshire pigs after i.v. administration of NA (1 mg) and before and after propranolol infusion (1 mg/kg). Real‐time interstitial NPY levels were measured using ventricular capacitive immunoprobes (CIs) affixed with NPY antibodies and quantified as the change in CI input current (INPY) upon binding of NPY. Interstitial NA was measured with adjacent fast‐scan cyclic voltammetry probes (INA). A left ventricular pressure catheter and continuous ECGs were used for haemodynamic recordings, and an epicardial 56‐electrode sock was used for measurements of activation recovery interval, a surrogate of action potential duration. Upon administration of NA, heart rate and left ventricular pressure increased, and activation recovery interval shortened. Notably, NA significantly increased interstitial myocardial NPY levels. After propranolol, changes in heart rate and activation recovery interval were largely mitigated. The INA increased to a similar extent post‐propranolol vs. pre‐propranolol, but changes in INPY were significantly reduced post‐propranolol. Coronary sinus plasma analyses confirmed fast‐scan cyclic voltammetry and CI findings. Hence, this study demonstrates that circulating NA induces NPY release from ventricular sympathetic nerve terminals, the mechanism for which is mediated via β‐adrenergic receptors and can be blocked by the non‐selective β‐blocker, propranolol. Key points Cardiovascular disease is characterized by sympathovagal imbalance, with increased plasma noradrenaline (NA) and neuropeptide Y (NPY) concentrations. Increased NPY levels are associated with increased ventricular arrhythmias and mortality in heart failure. Limited data are available on the specific factors that cause NPY release. In this study, fast‐scan cyclic voltammetry and capacitive immunoprobes were used to allow for real‐time in vivo measurements of interstitial myocardial neurotransmitters and neuropeptides, respectively. Using an in vivo porcine model with cardiac fast‐scan cyclic voltammetry and capacitive immunoprobes, it was shown that systemic NA can increase ventricular interstitial NPY levels, suggesting that NA induces NPY release from postganglionic sympathetic nerves. The release of NPY was blocked by administration of the non‐selective β‐blocker propranolol, suggesting that release of NPY is dependent on activation of β‐adrenergic receptors by NA.

The cardiac sympathetic co-transmitter neuropeptide-Y is pro-arrhythmic in human cardiomyocytes by lengthening activation-recovery interval

Bayliss Starling Prize Lecture 2023: Neuropeptide‐Y being 'unsympathetic' to the broken hearted

Relation of plasma neuropeptide-Y with myocardial function and infarct severity in acute ST-elevation myocardial infarction

Abstract 17032: Substrate Stiffness Alters the Kinetics of Sodium Channel Nav1.5 and Depolarization of Cardiomyocytes

An Animal And Clinical Study On The Change Of Neuropeptide Y Release Evoked By Electrical Stimulation And Myocardial Ischemia

Neuropeptide Y induced increase of cytosolic and nuclear Ca2+ in heart and vascular smooth muscle cells

Circulating noradrenaline leads to release of neuropeptide Y from cardiac sympathetic nerve terminals via activation of β‐adrenergic receptors

Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction

Abstract 4142660: Mast Cell MRGPRX2 Receptor-Mediated Neuroimmune Interaction Induces Ventricular Arrhythmias after Acute Myocardial Infarction Via the Overactivation of Cardiac Sympathetic Nerves System

NPY and cardiac diseases

Cardiac Sympathetic Nerve Sprouting and Susceptibility to Ventricular Arrhythmias after Myocardial Infarction

Non-invasive assessment of proarrhythmic risks associated with isoprenaline and the dietary supplement ingredient synephrine using human induced pluripotent stem cell-derived cardiomyocytes

Bioelectronic block of stellate ganglia mitigates pacing‐induced heterogeneous release of catecholamine and neuropeptide Y in the infarcted pig heart

Ventricular hyperinnervation in a mouse model of catecholaminergic polymorphic ventricular tachycardia

NaV1.8 as Proarrhythmic Target in a Ventricular Cardiac Stem Cell Model

Higher Sodium Channel Excitability in Cardiac Purkinje Fibers: Implications for Multifocal Ectopic Purkinje-Related Premature Contractions.

Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission

Nerve Sprouting Contributes to Increased Severity of Ventricular Tachyarrhythmias by Upregulating Iglurs in Rats with Healed Myocardial Necrotic Injury

Neuropeptide Y damages the integrity of mitochondrial structure and disrupts energy metabolism in cultured neonatal rat cardiomyocytes

Patient-specific Induced Pluripotent Stem Cell Properties Implicate Ca2+-homeostasis in Clinical Arrhythmia Associated with Combined Heterozygous RYR2 and SCN10A Variants.

Changes in Neuropeptide Y Y1 Receptor mRNA Level in the Infarcted Myoc ardial Tissues of Rats